AN2 Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AN2 Therapeutics, Inc. (ANTX) on September 7, 2023, covering events occurring on September 1, 2023. The company is a Delaware corporation headquartered in Menlo Park, California, and its common stock trades on The Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The primary material change reported is a shift in senior financial leadership effective September 1, 2023:
- Appointment: Lucy Day, currently the Chief Financial Officer and Principal Financial Officer, was appointed as the new Principal Accounting Officer.
- Departure: Michael Nazak, Vice President, Corporate Controller and the prior Principal Accounting Officer, will depart the company effective September 15, 2023.
- Hiring: Annie Yoshiyama, formerly Senior Vice President, Finance and Chief Accounting Officer at Tricida, Inc., was hired as the new Vice President, Finance and Corporate Controller.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The document serves solely to disclose the aforementioned officer appointments and departures.
Key Facts for Investor Verification
- Verify the transition timeline for the Principal Accounting Officer role between Lucy Day and Michael Nazak.
- Confirm the background and prior experience of the newly hired Vice President, Finance and Corporate Controller, Annie Yoshiyama.
- Review the definitive proxy statement (Schedule 14A) filed on April 26, 2023, for detailed biographical data on Lucy Day.